Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish University Hospital

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2739-2748

  Garcia Effron, Guillermo ^a   Canton, Emilia ^b   Pemán, Javier ^b   Dilger, Amanda ^a   Romá, Eva ^b   Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

C. metapsilosis; C. orthopsilosis; C. parapsilosis; FKS

Indexed keywords

ECHINOCANDIN;

ADOLESCENT; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CHILD; FEMALE; FUNGEMIA; FUNGUS ISOLATION; HUMAN; INFANT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; SPAIN; YOUNG ADULT;

EID: 84867606836     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks271     Document Type: Article

References (59)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
2. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
3. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-5.
4. Brito LR, Guimaraes T, Nucci M et al. Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol 2006; 44: 261-6.
5. Cuenca-Estrella M, Rodero L, Garcia-Effron G et al. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 2002; 49: 981-7.
6. Peman J, Canton E, Orero A et al. [Epidemiology of candidemia in Spain-Multicenter study]. Rev Iberoam Micol 2002; 19: 30-5.
7. Peman J, Canton E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23-30.
8. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 842-9.
9. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol 2000; 17: 73-81.
10. Cassone A, De Bernardis F, Pontieri E et al. Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis 1995; 171: 967-75.
11. Kato M, Ozeki M, Kikuchi A et al. Phylogenetic relationship and mode of evolution of yeast DNA topoisomerase II gene in the pathogenic Candida species. Gene 2001; 272: 275-81.
12. Lehmann PF, Lin D, Lasker BA. Genotypic identification and characterization of species and strains within the genus Candida by using random amplified polymorphic DNA. J Clin Microbiol 1992; 30: 3249-54.
13. Lin D, Wu LC, Rinaldi MG et al. Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 1995; 33: 1815-21.
14. Nosek J, Tomaska L, Rycovska A et al. Mitochondrial telomeres as molecular markers for identification of the opportunistic yeast pathogen Candida parapsilosis. J Clin Microbiol 2002; 40: 1283-9.
15. Roy B, Meyer SA. Confirmation of the distinct genotype groups within the form species Candida parapsilosis. J Clin Microbiol 1998; 36: 216-8.
16. Scherer S, Stevens DA. Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol 1987; 25: 675-9.
17. Tavanti A, Davidson AD, Gow NA et al. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-92.
18. Varga I, Soczo G, Kardos G et al. Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother 2008; 62: 1466-8.
19. van Asbeck E, Clemons KV, Martinez M et al. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62: 106-9.
20. Szabo Z, Szilagyi J, Tavanti A et al. In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology. Diagn Microbiol Infect Dis 2009; 64: 283-8.
21. Silva AP, Miranda IM, Lisboa C et al. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009; 47: 2392-7.
22. Orsi CF, Colombari B, Blasi E. Candida metapsilosis as the least virulent member of the 'C. parapsilosis' complex. Med Mycol 2010; 48: 1024-33.
23. Mirhendi H, Bruun B, Schonheyder HC et al. Molecular screening for Candida orthopsilosis and Candida metapsilosis among Danish Candida parapsilosis group blood culture isolates: proposal of a new RFLP profile for differentiation. J Med Microbiol 2010; 59: 414-20.
24. Lockhart SR, Messer SA, Pfaller MA et al. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-64.
25. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-9.
26. Gacser A, Schafer W, Nosanchuk JS et al. Virulence of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 2007; 44: 1336-41.
27. Diekema DJ, Messer SA, Boyken LB et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009; 47: 3170-7.
28. Canton E, Espinel-Ingroff A, Peman J et al. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 2010; 54: 2194-7.
29. Tavanti A, Hensgens LA, Ghelardi E et al. Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45: 1455-62.
30. Asadzadeh M, Ahmad S, Al Sweih N et al. Rapid molecular differentiation and genotypic heterogeneity among Candida parapsilosis and Candida orthopsilosis strains isolated from clinical specimens in Kuwait. J Med Microbiol 2009; 58: 745-52.
31. Sabino R, Sampaio P, Rosado L et al. New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol 2010; 48: 1677-82.
32. Goncalves SS, Amorim CS, Nucci M et al. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 2010; 16: 885-7.
33. van Asbeck EC, Clemons KV, Markham AN et al. Correlation of restriction fragment length polymorphism genotyping with internal transcribed spacer sequence, randomly amplified polymorphic DNA and multilocus sequence groupings for Candida parapsilosis. Mycoses 2009; 52: 493-8.
34. White TJ, Bruns TD, Lee SB et al. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ et al. eds. PCR Protocols: A Guide to Methods and Applications. San Diego, CA, USA: Academic Press Inc., 1990; 315-22.
35. Garcia-Effron G, Katiyar SK, Park S et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-12.
36. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
37. Kocsube S, Toth M, Vagvolgyi C et al. Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol 2007; 56: 190-5.
38. de Toro M, Torres MJ, Maite R et al. Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect 2011; 17: 418-24.
39. Tay ST, Na SL, Chong J. Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol 2009; 58: 185-91.
40. Torres CS, Dupla AM, Perez DR et al. [Nosocomial Candida infections and thrombocytopenia in very low birth weight newborns]. An Pediatr (Barc) 2007; 67: 544-7.
41. San Miguel LG, Cobo J, Otheo E et al. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005; 26: 548-52.
42. Marco F, Danes C, Almela M et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 2003; 46: 259-64.
43. Lopez Sastre JB, Coto Cotallo GD, Fernandez CB. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003; 20: 153-63.
44. Thierry G, Morio F, Le Pape P et al. [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-testw]. Pathol Biol (Paris) 2011; 59: 52-6.
45. Girmenia C, Martino P, De Bernardis F et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-14.
46. Cisterna R, Ezpeleta G, Telleria O et al. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol 2010; 48: 4200-6.
47. Duran MT, Velasco D, Canle D et al. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)]. Enferm Infecc Microbiol Clin 2003; 21: 488-92.
48. Paugam A, Baixench MT, Taieb F et al. [Emergence of Candida parapsilosis candidemia at Cochin hospital. Characterization of isolates and search for risk factors.]. Pathol Biol (Paris) 2011; 59: 44-7.
49. Segal BH, Kwon-Chung J, Walsh TJ et al. Immunotherapy for fungal infections. Clin Infect Dis 2006; 42: 507-15.
50. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
51. Kuhn DM, Mikherjee PK, Clark TA et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004; 10: 1074-81.
52. Levin AS, Costa SF, Mussi NS et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998; 30: 243-9.
53. Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11-6.
54. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14: 756-66.
55. Pavlovsky M, Weinstein R. Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: prospective observations of an emerging syndrome. J Clin Apher 1997; 12: 159-64.
56. Safdar A, van Rhee F, Henslee-Downey JP et al. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873-8.
57. Chen YC, Lin YH, Chen KW et al. Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan. Diagn Microbiol Infect Dis 2010; 68: 284-92.
58. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-9.
59. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.